8-K 1 d381472d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2017

 

 

Baxter International Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   1-4448   36-0781620

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

One Baxter Parkway, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

(224) 948-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(e) of the Exchange Act  ☐

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective May 1, 2017, Giuseppe Accogli, formerly the Corporate Vice President and President, Renal of Baxter International Inc. (the “Company”), changed roles and has assumed the role of Senior Vice President and President, Global Businesses. Brik Eyre, formerly the Corporate Vice President and President, Hospital Products of the Company, changed roles and has assumed the role of Senior Vice President and President, Americas effective as of the same date. These changes were made in connection with the Company’s continuing portfolio management and transformation efforts.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 2, 2017, the Company held its annual meeting of stockholders. Of the 541,957,424 shares outstanding and entitled to vote, 463,286,811 shares were represented at the meeting, constituting a quorum of approximately 85.5%. The following is a summary of the matters voted on at the meeting.

 

(a) The eight nominees for director were elected as follows:

 

Nominee

   For    Against    Abstain    Broker Non-
Votes

José (Joe) Almeida

   384,103,720    21,180,292    5,904,089    52,098,710

Thomas F. Chen

   400,745,186    9,978,717    464,198    52,098,710

John D. Forsyth

   393,067,950    17,639,528    480,623    52,098,710

Munib Islam

   392,787,890    17,887,002    513,209    52,098,710

Michael F. Mahoney

   400,763,563    9,941,483    483,055    52,098,710

Carole J. Shapazian

   399,898,863    10,840,154    449,084    52,098,710

Thomas T. Stallkamp

   392,184,503    18,527,024    476,574    52,098,710

Albert P.L. Stroucken

   396,538,427    14,174,655    475,019    52,098,710

 

(b) By the following vote, stockholders approved, on an advisory basis, the 2016 compensation paid to the Company’s named executive officers:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

397,027,576

  13,170,037   990,488   52,098,710

 

(c) By the following vote, shareholders recommended, on an advisory basis, to hold an advisory vote on executive compensation on an annual basis:

 

Every Year

 

Every Two Years

 

Every Three Years

 

Abstain

 

Broker Non-Votes

362,847,120

  1,936,480   45,599,733   804,768   52,098,710

The Company will include an advisory shareholder vote on executive compensation in its proxy materials every year until the next required advisory vote on the frequency of shareholder votes on executive compensation.

 

(d) The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2017 was ratified by the following vote:

 

For

 

Against

 

Abstain

451,261,925

  9,277,776   2,747,110

 

(e) By the following vote, stockholders did not approve the stockholder proposal relating to amending the proxy access bylaw to increase the stockholder aggregation cap:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

115,315,542

  293,964,705   1,907,854   52,098,710


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2017

 

BAXTER INTERNATIONAL INC.
 

/s/ Sean Martin

By:   Sean Martin
  Senior Vice President and General Counsel